From the Left · Read · October 23, 2026
Oct 22 · Moderna and Merck's personalized mRNA melanoma vaccine cuts the risk of recurrence or death by 42%, and Moderna shares tumble after the data leaks early
CNN: Experimental mRNA vaccine cuts risk melanoma returns by 42%
Grade F (52/100). The Phase 3 result (42% lower risk of recurrence or death with Keytruda), how the tailor-made shot works, a trial patient, the early release after the leak and the stock drop
Lehrer score 52/100 (−12 loaded wording: ¶1: 'oncologists and the public alike were exhilarated' (loaded, unsourced characterization in the outlet's own voice); −24 own-voice claim/analysis: ¶2: 'opening a path for an entirely new way to treat the disease' (own-voice claim about an unapproved therapy); −12 loaded wording: ¶13: Keytruda, 'which itself was revolutionary when approved in 2014' (verdict in the outlet's own voice)). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → F.
¶1: 'oncologists and the public alike were exhilarated' (loaded, unsourced characterization in the outlet's own voice); ¶2: 'opening a path for an entirely new way to treat the disease' (own-voice claim about an unapproved therapy); ¶13: Keytruda, 'which itself was revolutionary when approved in 2014' (verdict in the outlet's own voice)
Splits: The Phase 3 result (42% lower risk of recurrence or death with Keytruda), how the tailor-made shot works, a trial patient, the early release after the leak and the stock drop
- Broken. Rule: loaded wording (¶1: 'oncologists and the public alike were exhilarated' (loaded, unsourced characterization in the outlet's own voice))
- Broken. Rule: own-voice claim/analysis (¶2: 'opening a path for an entirely new way to treat the disease' (own-voice claim about an unapproved therapy))
- Broken. Rule: loaded wording (¶13: Keytruda, 'which itself was revolutionary when approved in 2014' (verdict in the outlet's own voice))
Same story: Forbes, Just the News